HIV Drug Aiming to Free Patients From Daily Doses Nears Market
- Glaxo’s ViiV sees long-acting shot hitting market early 2020
- Drugmaker hopes treatment will help it compete with Gilead
This article is for subscribers only.
A once-a-month shot promising to free patients from daily doses of treatment for HIV, the virus that causes AIDS, is expected to reach the market early next year after hitting goals in a pair of studies.
Monthly injections of two experimental drugs worked as well as a standard daily oral combination of three medicines in subduing HIV, according to a statement Thursday from ViiV Healthcare, a joint venture of companies led by GlaxoSmithKline Plc.